NARA Discovery
NARA Subscribed Scholarly Literature Discovery
Boolean search: climate AND coral · microplastic OR nanoplastic · plastic NOT freshwater · "marine heatwave"
Advanced Search
Topic searches article titles and abstracts. Starts a new search; publisher and year refine it.
Searches article titles and abstracts.
Accepts bare DOI, doi: prefix, or a doi.org URL.
Complete publisher name. Publisher imprints are grouped under their main publisher where applicable.
Exact match by full journal title or ISSN.
–
Refine Results Clear Filters
Collection
NARA Subscribed2
Publisher
Springer Nature2
Journal
European Journal of Clinical Microbiology & Infectious Diseases2
Publication Year
20191
20181
Graham Wetherill results 2 · Newest (Page 1/1, per page 25)
Export CSV Export RIS Export current results · up to 5,000 records
Author: Graham Wetherill ×Clear All Filters
Search Results
Correction to: Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE)NARA Subscribed
European Journal of Clinical Microbiology & Infectious Diseases · 2019 · Vol. 38 · Issue 1 · Springer
Maria J. G. T. Vehreschild; Surabhi Taori; Simon D. Goldenberg; Florian Thalhammer; Emilio Bouza; Joop van Oene; Graham Wetherill; Areti Georgopali
View Details View Full Text
Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE)NARA Subscribed
European Journal of Clinical Microbiology & Infectious Diseases · 2018 · Vol. 37 · Issue 11 · Springer
Maria J. G. T. Vehreschild; Surabhi Taori; Simon D. Goldenberg; Florian Thalhammer; Emilio Bouza; Joop van Oene; Graham Wetherill; Areti Georgopali
Information is limited or lacking on fidaxomicin treatment of Clostridium difficile infection (CDI) in patients with inflammatory bowel disease, fulminant or life-threatening CDI, severe renal impairment, moderate-to-severe hepatic impairment and pregnancy. The ANEMONE study investigated fidaxomicin use in a routine clinical setting, focusing on these medical conditions of specific interest (MCSIs). This retrospective, post-au...
View Details View Full Text